|
Exosomal Drug Delivery
|
1R44CA221487-01
|
$719,680
|
$719,680
|
GUPTA, RAMESH
|
3P BIOTECHNOLOGIES, INC.
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: Human Phase 1 safety and dose escalation studies
|
2R44CA162629-02A1
|
$1,154,726
|
$1,154,726
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
2R44CA210817-02
|
$1,101,350
|
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S1
|
$50,000
|
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S2
|
$149,785
|
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
The Madrina Network Web Portal
|
3R44CA177037-03S1
|
$34,313
|
|
MATIELLA, ANA
|
ACMA SOCIAL MARKETING
|
|
Innovation Corp Program and Commercialization Planning for Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
3R43CA225169-01S1
|
$49,999
|
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
Fluorescent Nanodiamonds for Multiplexed Imaging and Diagnostics
|
1R43CA232901-01
|
$291,083
|
|
SHENDEROVA, OLGA
|
ADAMAS NANOTECHNOLOGIES, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Oral formulation for novel inhibitor of Ras driven cancers
|
1R43CA217502-01A1
|
$300,000
|
$99,000
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, LLC
|
|
Oral formulation for novel inhibitor of Ras driven cancers
|
3R43CA217502-01A1S1
|
$2,000
|
$660
|
CANZONERI, JOSHUA
|
ADT PHARMACEUTICALS, LLC
|
|
Implantable iontophoresis chemotherapy delivery device for direct infusion of gemcitabine into pancreatic adenocarcinoma: Device development and First-in-Human clinical trial
|
4R44CA224460-02
|
$1,111,364
|
|
DAUNCH, WILLIAM
|
ADVANCED CHEMOTHERAPY TECHNOLOGIES, INC.
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation
|
1R43CA232977-01
|
$298,444
|
|
MARLEAU, ANNETTE
|
AETHLON MEDICAL, INC.
|
|
Training African Pathologists in Cancer Diagnosis
|
1R13CA232439-01
|
$38,120
|
|
WILSON, MICHAEL
|
AFRICAN STRATEGIES /ADVANCING PATHOLOGY
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
$255,230
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
$364,614
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Synergistic co-targeting of pro-apoptotic BAX and anti-apoptotic BCL-XL in cancer
|
1F31CA236434-01
|
$44,524
|
|
LOPEZ-ARROYO, ANDREA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
5R01CA077263-18
|
$417,500
|
$137,775
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Tumor expressed B7x accelerates disease and is a novel target for immunotherapy
|
5F31CA183493-04
|
$49,044
|
$16,185
|
OHAEGBULAM, KIM
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The Metastatic Cascade: Macrophages Lead the Way
|
5R01CA172451-06
|
$439,400
|
$145,002
|
POLLARD, JEFFREY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
RCT of An Internet Cessation Program Plus Online Social Network for HIV + Smokers
|
5R01CA192954-04
|
$634,880
|
$634,880
|
SHUTER, JONATHAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Methylome characterization of bronchial epithelial projenitor cells
|
1R21CA209436-01A1
|
$216,172
|
$216,172
|
SPIVACK, SIMON
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Develop and Apply a Novel Genome-wide Mendelian Randomization Method to Examine Relationship between Obesity and Lung Cancer
|
5R21CA202529-02
|
$208,405
|
$208,405
|
WANG, TAO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-05
|
$346,525
|
$69,305
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Novel IL-15 Superagonist Therapy for Bladder Cancer
|
6R44CA156740-05
|
$999,919
|
|
RHODE, PETER
|
ALTOR BIOSCIENCE. LLC
|
|
Highly Multiplexed Nanoscale Mass Spectrometric Imaging of Cancer Tissues
|
1R43CA236097-01
|
$300,000
|
|
LIM, MARK
|
AMBERGEN, INC
|
|
11th AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved
|
1R13CA236113-01
|
$74,000
|
|
FOTI, MARGARET
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
Integrative Molecular Epidemiology Workshop
|
2R25CA174664-06
|
$258,400
|
|
SELLERS, THOMAS
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
Colon cancer risk-stratification via optical analysis of rectal ultrastructure
|
3R44CA199667-02S1
|
$2,000
|
|
WALI, RAMESH
|
AMERICAN BIOOPTICS, LLC
|
|
Colon cancer risk-stratification via optical analysis of rectal ultrastructure
|
3R44CA199667-02S2
|
$126,060
|
|
WALI, RAMESH
|
AMERICAN BIOOPTICS, LLC
|
|
Imaging and Radiation Oncology Core (IROC) Group
|
3U24CA180803-05S1
|
$335,460
|
|
FOLLOWILL, DAVID
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
AMERICAN S FOR NONSMOKERS RIGHTS SMOKEFREE ORDINANCES DATA -- CATALOG # : 1
|
261201700689P
|
$16,550
|
$16,550
|
UNKNOWN, UNKNOWN
|
AMERICAN NONSMOKERS RIGH
|
|
Practical high resolution microscopy of un-cut, un-embedded lung biopsies
|
2R44CA189522-02
|
$1,091,279
|
$1,091,279
|
LEVENE, MICHAEL
|
APPLIKATE TECHNOLOGIES, LLC
|
|
Novel approaches to study immune responses to post translational modifications for cancer detection
|
5U01CA214201-02
|
$462,286
|
$231,143
|
LABAER, JOSHUA
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Couple Communication in Cancer: A Multi-Method Examination
|
3R01CA201179-03S1
|
$227,376
|
|
LANGER, SHELBY
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Therapeutic peptide for hepatocellular carcinoma
|
1R43CA232947-01
|
$299,983
|
|
PANDEY, NIRANJAN
|
ASCLEPIX THERAPEUTICS, LLC
|
|
Create three-member project team to refine commercialization plans for AML-Mutation Counter, a tool to detect residual and recurrent leukemia.
|
3R41CA213690-01S1
|
|
|
KAUFMANN, WILLIAM
|
ASYSTBIO LABORATORIES, LLC
|
|
P53-dependent immunogenic DCs in the tumor microenvironment
|
1R50CA232983-01
|
$203,853
|
|
SHARMA, MADHAV
|
AUGUSTA UNIVERSITY
|
|
DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer
|
1R44CA232963-01
|
$299,937
|
|
GLODE, MIKE
|
AURORA ONCOLOGY, INC.
|
|
Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy
|
1R44CA233143-01
|
$218,588
|
|
LAMPI HERMANSON, DAVID
|
B-MOGEN BIOTECHNOLOGIES, INC.
|
|
Integrative Oncology: From Research to Practical Applications
|
1R13CA236121-01
|
$5,000
|
|
RAO, SANTOSH
|
BANNER HEALTH
|
|
Research Supplements to Promote Sharing Data in Cancer Epidemiology Studies
|
3U19CA203654-02S1
|
$147,830
|
$147,830
|
AMOS, CHRISTOPHER
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Psychosocial Intervention for the Caregivers of Advanced Lung Cancer Patients
|
5R01CA187143-04
|
$456,456
|
$456,456
|
BADR, HODA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Cancer-associated fibroblast in the regulation of bladder cancer stem cells
|
3R01CA175397-05S1
|
$110,950
|
|
CHAN, KEITH SYSON
|
BAYLOR COLLEGE OF MEDICINE
|
|
ALK causes TGF-beta insensitivity in lung cancer cells
|
5R21CA209007-02
|
$206,843
|
$206,843
|
FENG, XIN-HUA
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and Targeting Onocgenic MYC Enhancer Control in Pediatric Tumors
|
3R01CA215452-02S2
|
$45,800
|
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Lung Cancer Prediction Models Incorporating Exome Data from Extreme Phenotypes
|
5K07CA181480-04
|
$127,883
|
$127,883
|
LIU, YANHONG
|
BAYLOR COLLEGE OF MEDICINE
|
Total relevant funding to Lung for this search: $349,089,523
|